company background image
VXRT logo

Vaxart NasdaqCM:VXRT Stock Report

Last Price

US$0.60

Market Cap

US$136.5m

7D

3.4%

1Y

-16.7%

Updated

24 Nov, 2024

Data

Company Financials +

Vaxart, Inc.

NasdaqCM:VXRT Stock Report

Market Cap: US$136.5m

VXRT Stock Overview

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. More details

VXRT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 45.24% per year

Risk Analysis

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years


Vaxart, Inc. Competitors

Fennec Pharmaceuticals

NasdaqCM:FENC

US$145.9m

Compugen

NasdaqCM:CGEN

US$126.2m

Pyxis Oncology

NasdaqGS:PYXS

US$113.0m

Adaptimmune Therapeutics

NasdaqGS:ADAP

US$169.3m

Price History & Performance

Summary of all time highs, changes and price drops for Vaxart
Historical stock prices
Current Share PriceUS$0.60
52 Week HighUS$1.54
52 Week LowUS$0.52
Beta0.70
11 Month Change-27.12%
3 Month Change-31.90%
1 Year Change-16.70%
33 Year Change-91.98%
5 Year Change84.62%
Change since IPO-92.94%

Recent News & Updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Recent updates

Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

Nov 16
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding

There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

Aug 20
There's Reason For Concern Over Vaxart, Inc.'s (NASDAQ:VXRT) Massive 39% Price Jump

An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Jun 15
An Intrinsic Calculation For Vaxart, Inc. (NASDAQ:VXRT) Suggests It's 26% Undervalued

Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Nov 08
Here's Why Vaxart (NASDAQ:VXRT) Must Use Its Cash Wisely

Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Jun 30
Vaxart (NASDAQ:VXRT) Will Have To Spend Its Cash Wisely

Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis

Sep 09

Ray Stapleton joins Vaxart as CTO

Aug 31

Vaxart shareholders approve proposal to increase number of shares

Aug 05

Vaxart continues to lobby shareholders to vote to increase number of shares

Jul 29

Vaxart oral COVID-19 pill vaccine candidate induces long-lasting antibodies against SARS-CoV-2

Jul 20

Vaxart says recent CRO agreement 'may be integral' to oral COVID vaccine success

Jul 07

Vaxart: A Unique Vaccine Concern

Jun 14

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

Feb 26

Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow

Dec 09

Vaxart: Differentiated Covid Oral Route Remains Viable

Nov 16

Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program

Oct 30

Shareholder Returns

VXRTUS BiotechsUS Market
7D3.4%2.5%2.2%
1Y-16.7%16.1%31.6%

Return vs Industry: VXRT underperformed the US Biotechs industry which returned 16.1% over the past year.

Return vs Market: VXRT underperformed the US Market which returned 31.6% over the past year.

Price Volatility

Is VXRT's price volatile compared to industry and market?
VXRT volatility
VXRT Average Weekly Movement8.2%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: VXRT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VXRT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a109Steven Lovaxart.com

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral.

Vaxart, Inc. Fundamentals Summary

How do Vaxart's earnings and revenue compare to its market cap?
VXRT fundamental statistics
Market capUS$136.49m
Earnings (TTM)-US$72.34m
Revenue (TTM)US$16.76m

8.1x

P/S Ratio

-1.9x

P/E Ratio

Is VXRT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VXRT income statement (TTM)
RevenueUS$16.76m
Cost of RevenueUS$68.14m
Gross Profit-US$51.38m
Other ExpensesUS$20.96m
Earnings-US$72.34m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin-306.58%
Net Profit Margin-431.61%
Debt/Equity Ratio7.1%

How did VXRT perform over the long term?

See historical performance and comparison